Thank you, Brad.
But for moment the The watershed are here company distant we first seem memory. our today we a a believe quarter like significant and represents on reporting may that future. it
This represented history clearance. product. treatment No other than be FDA first any First, sleep to advancement oral oral mild January, announced of received FDA in recognized mechanism underestimated. XXX(k) flagship time product the our the should early significance a for in mandibular DNA of the appliance action appliance we for apnea. of this not in such has clearance oral an And appliance breakthrough ever that the obstructive moderate
years DNA of time compelling real-world with We that appliance believe and our treatment symptoms fully XX% the after seeing patients persuaded finally FDA, yet remarkable resolve Method. were by Vivos using several data. of the completely the This forth a going round submission they showing of of back and OSA their after another
of and Now five required. that treatment no OSA, meeting five to showed was be or AHI longer out higher clear, further scores clinical intervention of no in present patients with after this four data
in unparalleled As product by medicine, or such far any therapy. know, unprecedented results sleep we other are clinical as and
alter We to include treatment clearance more expect of financial be regulatory their our realized to sales impact the time that over DNA plans appliances. doctors as on full
regarding institutional Second, single trade heels from this and our from raised for and appliance, trademarks, investor. immediately good million proceeds the of DNA patents, product with on net equity Facialdontics. expanding of intellectual roughly an of put We tranche certain our the clearance the acquisition capital the to $X.X Advanced through announcement we property secrets FDA and use a suite
That quarter. position headaches, and towards to -- migraine at a to sleep but resistance, that on of it maintain and conditions also end providers suite first in other linked fills market-leading apnea, TMD treatments this nasal the Vivos product transaction closed to ensures conditions, and its closely technological obstructive of such as patients not only forefront We for bruxism, acquisition patients. certain the offerings pain, gap our and the will
in people pain from million XX issues. TMD Nearly States suffer the related United and
suffer million from their XX difficulty or migraine breathing headaches Another nose. have through
in patented conditions. be new shown unilateral Our technology has bite block been highly to treating such effective
cash XXXX. levels staffing as we reduce the to company push to reorganizing now the in mentioned, and the breakeven, we quarter, of our order which, quarter rightsizing our first Brad of burn the during closer Also, process accelerated expect our corporate cash flow during management to first and achieve team
in will serve we we reductions look event, in and here reduction force As overhead. further our prudent these announced a think subsequent necessary early actions we the of Again, quarter, us a improve results second to well as and operations. in
operations current organizations as pilot including in DSOs On DSO DSOs, pilots X,XXX known our the we side, representing new important certain with of over the progress and made with eight regional national execution and locations nationwide. existing tests
highlight DSO, XX all the in states to particular name operates I'd Toothpillow. which one like under
orofacial issues and ADD, of breeding, the development. crowded use between teeth, estimated through in from associated with be of which our direct-to-consumer has exceptional and Vivos challenges, strides Over the and ages of pediatric behavioral exclusively growth An cultivating for and may chronic and all making suffer Toothpillow past related sleep oral forward mouth ADHD, XX million bed wetting, growth products various and development. been XX developmental geared allergies, months, helped scholastic Guides children crooked a towards X XX issues, channel problems, breathing guided proper
telehealth, focus are we of a field Toothpillow on to exclusive issues. orthodontic oral their particular with And related is set Vivos. pediatric a breathing is appliance and supplier. commercial treatment pioneering of partner redefine dental Toothpillow the
of This of leverages advancing the underscoring transformational in oral world-class cutting-edge appliances, delivery and relationship products orthodontic Vivos' care. pediatric role dental the our
holistic, partners high-quality serve and growing rapidly appliances solution network Vivos' XXX Toothpillow's telehealth of between boasts in-practice providers. base and Vivos-trained at-risk trading a highly as for creating that to skilled XX. practitioners of Toothpillow virtual X premium a and national over strong accessible, referral The synergy of pediatric XX patients dentists oral and software aged a is
seamless virtual national marketing between app Over XX% with care and mobile Toothpillow campaign, patients designed has paying Toothpillow's connections converting Despite have its services XX having featuring into a its patients all been the facilitate all not perfecting yet referrals states, proprietary of inquiries doctors. year sought by out past been already platform to launched in through patients. new
our up not about And believe avenue versatility growth. excited our we large Toothpillow. with relationship and of oral effectiveness showcases exciting and opens but is for the only Vivos new a appliances, it also
step tools them the healthcare professionals that and are will Toothpillow's bringing our us confident closer of treatment We best voices to in success industry, further technology very vision the the amplify training one available. providing with reputation and
it important, starting example have as XXXX DSOs and in enter we just one beyond. Toothpillow Equally to business into is several relationships of And of do to we been as an speaking therefore, and similar with. serves hope with
can And at agreement that are to nationally Also is a CPAP that provide announcing recognized company, national today, pilot a is this more Medical first non-exclusive planned Durable thousands XX-day rollout for of we of time. hundreds are execution alternatives. successful, DME, follow. distribution or If our pilot with serves the who nationwide, a Equipment we patients of seeking details
process. with distributors similar in agreements Other are potential
the further of as of diagnostic dental coaching through different act direction patients financial of help education, believe a revenue An impact We the show the insurance through quarters integral the efforts practice up guide doctor. that to the we last appointments, this the patient an patient steps treatment on these the this many program VIP will generally third Treatment fourth to coordinating of designed effectively under including top-line office that extension the introduced Navigator from and the was fall. treating of to the year. pre-authorizations, pilot program begin This continue in journey, to and is part
mitigate up case Treatment practice, a it significant the Treatment the will the Navigator we within center for associated expect profit which turnover services, the workload us. challenges and per anticipates from employee $XXX contributor become does program only It practice. to to with Vivos revenue significant removes helps Not Navigator soon for
streams, creating XXXX. achieve by will our focus cash of believe of first new We positive on flow to quarter our of revenue achieving stated the intense with an cost cutting, latest rounds goal allow us coupled
now prior equipment by their primary actively doctors, and -- patients to Our augmented offices demand into medical medical channels more. through dentists their multiple create clinics, suppliers, and health large employers, care including driving is reliance Vivos Vivos-trained practices distribution men's being within from on new specialty
growth. patients the Vivos organically to our potential qualified a fuel more to patients airway becomes deliver new we qualified cycle We more attractive. Vivos-trained more new our to as and airway compelling creates value proposition new that providers virtuous deliver It's to providers, potential
expect the half We see year. these begin the in impact of to strategic of to this initiatives latter
efforts, of last the journals. professional multiple respect quality the towards journals, produced efficacy and With published proving being single R&D past advancement our studies technology has year largest year in -- with papers this peer-reviewed to ongoing our top the
We will to controlled Stanford University are our to announce pleased trial, to of be recent execution CPAP. agreement compared with begin an a the where randomized today, appliances DNA directly
currently Additional new than are products and university-based significant Vivos and start publication. there pending no process showing Currently, have clinical expected are year-end. additional that trials papers been before are results to clinical five on less submitted in are
is market effect of for possesses that and sleep establish and on any advanced research disorders cumulative breathing to today. The the beyond reasonable single effective this doubt most the Vivos treatment
final product note front. our One development on
we in collecting own to engaged patients also and compliance mobile patient-driven the monitoring that and key a their and been time in actively in have development charge empowering of while will health app some diagnostic For assist take progress, now, patient data, wellness. of clinicians
and providers. interaction participate periodic their in providing and taking records, patients example, actually can feedback, with For receive coaching
delivery also platform services therapy, remote and important exercises, myofunctional as of for breathing certain mobile clinical such allows The more. notifications,
their that such off load while Vivos commercialized demand also and for believe is of to We the product that the by year. of it provider profitable for dentists ready and strong this Vivos available a taking leads by the highly and product have and be providers, for surveys to expect both a have and a us end app there version of Our can to a and teams. commercial feedback testing potential of this quarter beta plan month, fourth
in Now closing.
products technology that and and of evidence-based full the can have the of needs. We points spectrum address now the price needs across patients
We FDA clearances. have the
now trained both a awareness nationwide patients. growing and the providers of we And have providers. amongst brand network We have
cost, effects more yield the allow in will above top-line our the soon have access to before. to We Through outlined our revenue of distribution internal significant XXXX. new we strategic patients combined of growth self-sustaining than quarter cost new networks, initiatives ever revenue reductions, will potential believe become and us operating the first and
concludes prepared Operator? and remarks, be take our This now happy we'll to questions.
